Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A study to evaluate resource draining "no shows".
Chand AA, Kamble KM, Diwan AK, Mahobia VK, Chand DA. Chand AA, et al. Among authors: mahobia vk. J Cancer Res Ther. 2017 Jul-Sep;13(3):498-500. doi: 10.4103/0973-1482.162112. J Cancer Res Ther. 2017. PMID: 28862216 Free article.
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer.
Kothari R, Doshi M, Chaithanya PK, Ct S, Kumar A, Mallavarapu KM, Nagarkar R, Mahobia V, Bhatt N, Priyadarshini KL, Gogia A, Maksud T, Prasad S, Velavan K, L K R, Ss P, Talreja V, Kalra K, Nemade B, Dastidar AG, Gupta T, Patil T, Bondarde S, Patel P, Gupta S, Biswas G, Vaghela M, Mahato P, Parekh H, Kalloli M, Shetty R, Prakash G, Goel A, Mandal S, Choudhury T, Jain M, Goswami C, H M YK, Mukherjee KK, Shrivastava R, Parmar D. Kothari R, et al. Clin Breast Cancer. 2024 Oct;24(7):639-646.e2. doi: 10.1016/j.clbc.2024.07.001. Epub 2024 Jul 10. Clin Breast Cancer. 2024. PMID: 39069436 Clinical Trial.
Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial.
Prabhash K, Deshmukh C, Malhotra H, Sharma A, Jain M, Dhamne N, Nagarakar R, Ganesan P, Mahobia VK, Das CK, Kumar R, Shivanna PS, Avaronnan MP, Chaithanya PK, Chaudhary V, Singh K, Aagre S, Ravishankar B, Mehta D, Shilpa K, Maniar V, Chatterjee K, Majumdar SD, Dana R, Noronha V, Menon N, Sharma A, Pawar R, Shahavi V, Yadav R, Aiwale A. Prabhash K, et al. Among authors: mahobia vk. JCO Glob Oncol. 2024 Nov;10:e2400059. doi: 10.1200/GO.24.00059. Epub 2024 Nov 14. JCO Glob Oncol. 2024. PMID: 39541562 Clinical Trial.